Fidelis Capital Partners LLC Has $2.35 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Fidelis Capital Partners LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 107.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,313 shares of the company’s stock after buying an additional 10,500 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $2,351,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its holdings in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after buying an additional 37,346 shares in the last quarter. Independence Bank of Kentucky grew its holdings in shares of Novo Nordisk A/S by 192.7% during the 3rd quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock worth $1,368,000 after purchasing an additional 7,565 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Novo Nordisk A/S by 453.3% during the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock worth $34,095,000 after purchasing an additional 217,545 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth $1,624,000. Finally, Azzad Asset Management Inc. ADV grew its holdings in shares of Novo Nordisk A/S by 55.9% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 41,107 shares of the company’s stock worth $4,895,000 after purchasing an additional 14,731 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, October 10th. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $112.01 on Wednesday. The stock’s 50-day simple moving average is $125.68 and its 200 day simple moving average is $131.19. The firm has a market capitalization of $502.65 billion, a PE ratio of 38.36, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.66%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.